Based on the above results, it is proposed that STM2457 administration hinders tumor progression via ASNS downregulation, and high expression of ASNS may retard the anti-tumor effect of STM2457 in CRC cells in vitro and in vivo. The gene discussed is ASNS; the disease is neoplasm.